More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 -- Adaptive...

Related Keywords

Spain , Madrid , Chicago , Illinois , United States , University Of Chicago , American , Ciltacabtagene Autoleucel , Susan Bobulsky , Lisocabtagene Maraleucel , Obecabtagene Autoleucel , Brexucabtagene Autoleucel Brexu , Karina Calzadilla , Erica Jones , Idecabtagene Vicleucel Ide , Vendexv Pomalidomide , Exchange Commission , American Society Of Clinical Oncology , Acalabrutinib And Obinutuzumab , Adaptive Biotechnologies Corporation Nasdaq , European Hematology Association , Cancer Center Clinica Universidad De Navarra , Children Oncology Group , Corporate Communications , Biotechnologies Corporation , American Society , Clinical Oncology , Annual Meeting , Hybrid Congress , Oncology Group Led , Adults With , Refractoryb Cell Acute Lymphoblastic Leukemia , Overall Survival , Event Free Survival , The Open Label , Autoleucel In Adult , Safety Of Ciltacabtagene Autoleucel , Refractory Multiple Myeloma , Biomarker Subgroup , With Newly Diagnosed Multiple Myeloma , Analysis Of Minimal Residual Disease , Minimal Residual Disease , Autoleucel Vs Standard , Lenalidomide Refractory Multiple Myeloma , Analysis By Cytogenetic , Report From The Children , Oncology Group , Expanding The Clinical Utility , Maintenance Therapy , Plus Lenalidomide And Dexamethasone , With Bortezomib Versus Isard , After Idecabtagene Vicleucel , Pts From , Negativity To Full Dose Melphalan , First Line Treatment , Patients With Chronic Lymphocytic Leukemia , Resource Use And Cost , Therapy In Patients With , Refractory Chronic Lymphocytic Leukemia From , Induces Deep Responses , Relapsed Or Refractory , Follicular Lymphoma , Safety And Pooled Efficacy Data From , Measurable Residual Disease , Patients With Follicular Lymphoma , Results From , Residual Disease , Step Up Dosing , Patients With , Refractory Follicular Lymphoma , Withdr Maintenance , Newly Diagnosed Myeloma , Patients With Newly Diagnosed Multiple Myeloma , Final Overall Survival , Analysis From The , Adaptive Biotechnologie , Financial Condition , Vice President , Associate Corporate Communications ,